Fig. 2
From: Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
Diverse TP53 configurations and disease subtypes impact prognosis. A patients with single hit (left panel) vs. double hits (middle panel) TP53 lesions and the type of configuration for each hit class and various constellations among different myeloid neoplasms (right panel). B Kaplan–Meier survival estimates of patients with TP53 wild type, single hits, and double hits, all patients (left panel) and cases with missense (middle panel) and truncated mutations (right panel). C Kaplan–Meier survival estimates of patients with TP53 single hits and double hits distributed according to different disease subtypes: AML (left panel), MDS (middle panel), and MDS/MPN (right panel). D Kaplan–Meier survival estimates of patients with TP53 wild type and single hit distributed according to different disease subtypes: AML (left panel), MDS (middle panel), and MDS/MPN (right panel). E Kaplan–Meier survival estimates of TP53 double hits (left panel) and single hit (right panel) in acute myeloid leukemia (AML) vs. myelodysplastic syndrome (MDS) in correlation with variant allelic frequency (VAF) for each subtype